CABS 2020 Investor Forum and Entrepreneurship Club Innovation Roadshow

Date: January 15, 2020 @ 8:00 am – @ 4:30 pm
Location: Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482

Chinese American BioPharmaceutical Society (CABS) is pleased to announce that 2020 CABS Investor Forum will be held on January 15th of 2020 in conjunction with JP Morgan Healthcare Conference. This forum will feature a morning session and an afternoon session. The morning session will be joined by China- and US-based investors, business development executives, and entrepreneurs. The topics will focus on the trends, opportunities and challenges in capital investment, business development and M&A, in US and China Biopharma. The afternoon session will be CABS E-club Innovation Roadshow, where 6-8 start-up companies will give short presentations about their technologies.

Due to high demand and limited seats available, please sign up only when you are sure to attend!!! If your schedule changes after sign up, please cancel and leave the seat to others!!!

Online Registration Deadline is 1/10/2019 (Friday) 12am!!! 

No Walk-in Allowed; Only online registrants will be allowed admission!!!

Agenda (Preliminary)

Morning Session

8-8:50am: Registration and Networking

8:50-9:00am Opening Remark by Yang Tian, CABS President

9:00-9:20am Jonathan Norris, Managing Director, Silicon Valley Bank, Overview of US Biopharmaceutical Investment, Corporate Business Development and M&A.

9:20-10:20am Panel discussion 1: Trends, Challenges and Opportunities in US Biopharma Investment

Moderator: Janet Xiao, Partner, Morrison & Foerster LLP

Confirmed Panelists:

Jonathan Norris, Managing Director, Silicon Valley Bank

Ori Solomon, Partner, Morrison & Foerster LLP

Hong Zheng, VP, Ally Bridge

10:20-10:50am: Coffee Break and Networking

10:50-11:10am Greg Scott, Founder, ChinaBio, Overview of China Biopharmaceutical Investment, Corporate Business Development and M&A

11:10-12:00pm Panel Discussion 2: Trends, Challenges and Opportunities in China Biopharma investment (tentative panel theme)

Moderator: Alex Zhang, CEO, Hanhai Silicon Valley

Confirmed Panelists:

Tina Yu, Managing Partner, YuanMing Capital

Dandan Dong, Managing Director, Vivo Capital

Karen Liu, Founding Partner, 3E Bioventures Capital

Greg Scott, Founder, ChinaBio

Lusong Luo, Sr. Vice President, BeiGene

12:00-1:00pm Lunch and Networking

1:00pm End of morning program

 Afternoon Session

1:00-2:00pm Registration

2:00pm-4:00pm Innovation Roadshow 

Moderator: Huijun Zhou, CABS Entrepreneurship Club Program Chair 

 

Morning Session Panelists 

 

Morning Session Panelists 

Jonathan Norris, Managing Director, Silicon Valley Bank

Dr. Jonathan Norris is a managing director for the healthcare and life science practice for Silicon Valley Bank. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many life science and healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations. In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than sixteen years of banking experience working with healthcare companies and venture capital firms. Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

Ori Solomon, Partner, Morrison & Foerster

Ori Solomon is a partner in the Corporate Department and Co-chair of the firm’s Emerging Companies and Venture Capital practice.Mr. Solomon provides general corporate representation to a wide range of companies, from start-ups and emerging growth companies to large public companies.  Mr. Solomon also represents venture capital funds in a wide range of transactions, including investments in portfolio companies and secondary direct transactions.His transaction-based practice focuses primarily on representing emerging companies and their investors in a variety of venture and growth equity financings, secondary investments, mergers and acquisitions, joint ventures and other strategic transactions. Mr. Solomon has represented clients in a variety of industries, primarily life sciences and technology.  He is recognized as a leading lawyer by Legal 500 US for Media, Technology & Telecoms.Mr. Solomon also regularly represents both buyers and sellers in structuring, negotiating and documenting acquisitions involving public and private companies, and also has significant experience in public and private corporate finance transactions, including registered equity offerings, PIPEs and other alternative financing transactions. He regularly advises public company clients with respect to corporate governance issues, board of directors matters, SEC periodic reporting and other securities law compliance, proxy statements and annual meetings, disclosure controls and procedures, and Sarbanes-Oxley and other related matters.

Hong Zheng, PhD, Vice President, Ally Bridge Group

Dr. Hong Zheng is currently a Vice President at Ally Bridge Group (New York). He leads the investment research in the US Biotechnology public market. Dr. Zheng has over 10 years of experience in biomedicine, working across the fields of investment, industry, and academia. Before joining Ally Bridge Group, Dr. Zheng was a senior equity research associate at RBC (Royal Bank of Canada) Capital Markets, when he covered over 30 US biotech companies. Prior to RBC, Dr. Zheng was a lead chemist at Ra Pharmaceuticals (recently acquired by UCB), where he led the med-chem efforts of multiple drug discovery programs including small molecule and peptide drug candidates. Dr. Zheng completed his Bachelor’s degree at Fudan University and received his Ph.D. in Chemical Biology from Boston College. He is the lead author of numerous highly impactful research articles in top-ranked journals and the key inventor of several patents.

Janet Xiao, PhD, JD, Co-Chair of Global Life Sciences Group, Morrison & Foerster LLP

Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients’ complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She helps some of the world’s most-sophisticated biopharmaceutical companies and investors assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works regularly with patent litigators in the event of legal challenges by third-party competitors or vice versa, and she is frequently called upon to represent clients in litigation and post-grant proceedings. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Biopharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term.  

Greg B. Scott, Founder and Chairman, ChinaBio® Group

Greg founded ChinaBio® Group in 2007 to help life science companies and investors achieve success in China. ChinaBio® works with US, European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China. ChinaBio® has also organized over 30 conferences in China focused on cross-border investment and partnering, including the ChinaBio® Partnering Forum which draws over 1400 attendees from around the world to China each spring. Greg is also co-founder of two investment groups that have funded over 50 biotechnology and medical device companies in the US and China, and Executive Editor of ChinaBio® Today, a widely read newsletter covering the China life science industry. He also is the current chair for the American Chamber of Commerce Healthcare Committee, and a former board member of BayHelix Group. Greg is considered a leading expert on China’s life science industry and is frequently quoted in media including the Wall Street Journal, Financial Times, Bloomberg, BioWorld, BioCentury, and other industry publications. Headquartered in Shanghai, ChinaBio® has team members in San Diego, Palo Alto, and Basel, Switzerland. 

Tina Yu, PhD, Co-Founding Partner of YuanMing Capital

 Dr. Tina Tianning Yu has almost twenty years of professional experience working in the life sciences sector and the financing world of the healthcare industry. Dr. Yu is a Co-Founding Partner of YuanMing Capital, a healthcare specialty fund and CEO of Mevion Medical Systems. She led the investment in BeiGene, Ascentage Pharmaceuticals, and Mevion Medical Systems, etc. Prior to that, Dr. Yu worked for Vision Capital, a NYC-based investment management firm, as a Director of Investment, responsible for US biotech and China sectors. Before becoming an investor, Dr. Yu was a senior research scientist at Wyeth BioPharma, where she specialized in therapeutic protein development. Dr. Yu serves on the Board of Mevion Medical Systems, Alliance for Proton Therapy Access and USTC Alumni Association in Greater New York. She is a regional director of HBS Healthcare Alumni Association. Dr. Yu holds a PhD in Chemistry from Princeton University, an MBA from Harvard Business School, and a B.S. in Biology from University of Science and Technology of China.  

Dandan Dong, PhD, Managing Director, Vivo Capital

 Dandan Dong, Ph.D., is a Managing Director of Vivo Capital. She has a background in academic biomedical science research and translational medicine. She has more than eight years’ experience in healthcare investments in both the United States and China. As a member of Vivo’s cross-border strategy, she has been involved in multiple transactions in both countries and cross-border deals. She is the founding member of VISEN Pharmaceuticals and currently serves as VISEN’s Chief Business Officer. She is a managing member of Vivo PANDA Fund, Vivo’s early-stage investment vehicle. Dr. Dong holds a Ph.D. in biomedical science from Fudan University and she has completed the Pre-doctoral Fellowship program at New York University School of Medicine.

Karen Liu, PhD, Founding Partner of 3E Bioventures Capital

 Dr. Karen Liu has been active in China healthcare venture investment since 2005. She is a founding partner of 3E Bioventures Capital, a healthcare-focused venture investment firm actively investing in worldwide new drugs and innovative medical devices and diagnostics.Prior to 3E Bioventures, Dr. Karen Liu was a partner of Kaiwu Capital and Managing Director at CRCI Capital, in charge of healthcare investment. Dr. Karen Liu received her Ph.D in Immunology and Master of Medical Sciences degree from Harvard University, and Bachelor of Sciences degree from Cornell University. She also received an EMBA degree from CKGSB-Chungkong Graduate School of Business in China. 

Lusong Luo, PhD, Sr. Vice President, BeiGene

 Dr. Lusong Luo is currently SVP & Head of External Innovation at BeiGene. Prior to taking this role, Dr. Luo is SVP & Head of Discovery Biology at BeiGene. Dr. Luo is one of the founding scientists of BeiGene. Before joining BeiGene, Dr. Luo held positions in BioDuro as Sr. Director and Director of Discovery Biology. Dr. Luo has also spent a number of years at GlaxoSmithkline Oncology CEDD, where he served as Group Manager, Research Investigator, and Principal Scientist. Dr. Luo was a key member of a number of oncology drug discovery/development teams that have contributed to the discovery and development of around a dozen clinical compounds over the years. Dr. Luo has published over 50 research papers, reviews, and book chapters. He was trained with Professor. Christopher T Walsh at Harvard Medical School and obtained his Ph.D. in Biochemistry from University of New Mexico.

Alex Zhang, PhD, MBA, CEO of Hanhai Silicon Valley

Alex Zhang is the CEO of Hanhai Silicon Valley., an early stage investor and cross-border accelerator for startups in San Francisco Bay Area. Prior to Hanhai, Alex was the Managing Partner of Enverest, LLC., a Silicon Valley-based innovation solutions and investment advisory firm with branch offices in China and Singapore. Prior to co-founding Enverest, Dr. Zhang spent nearly five years at Thermo Fisher Scientific, where he was responsible for 4 business development deals exceeding $10 M, and played a key role in several billion-dollar acquisitions in MedTech. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas. Dr. Zhang received MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. During his graduate research, he focused on the design and synthesis of therapeutic peptoids, as well as biological mass spectrometry. His research has led to publication of more than 20 peer reviewed articles and 4 patents. Dr. Zhang has served multiple leadership roles in the Executive Council of CABS, including as the President in 2017-18. Over the past decade, Dr. Zhang has advised a number of successful MedTech and digital health startups based in Silicon Valley.          

 

Due to high demand and limited seats available, please sign up only when you are sure to attend!!! If your schedule changes after sign up, please cancel and leave the seat to others!!!

Online Registration Deadline is 1/10/2019 (Friday) 12am!!! 

No Walk-in Allowed; Only online registrants will be allowed admission!!!

Cannot Register Using iPhone? Click Here 

 

 

Online Free Registration – $0 (USD) - 32 left
Due to high demand and limited seats available, please sign up only when you are sure to attend.
VIP Registration – $0 (USD) - 50 left
Special Code Required